Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients

F Saladini; G Meini; C Bianco; L Monno; G Punzi; M Pecorari; V Borghi; M Di Pietro; G Filice; Gismondo; V Micheli; G Penco; T Carli; Andrea De Luca; M. Zazzi

doi:10.1111/j.1469-0691.2012.03917.x

Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients

F Saladini, G Meini, C Bianco, L Monno, G Punzi, M Pecorari, V Borghi, M Di Pietro, G Filice, Gismondo, V Micheli, G Penco, T Carli, Andrea De Luca, M. Zazzi

Università Cattolica del Sacro Cuore

Research output: Contribution to journal › Article

22 Citations (Scopus)

Abstract

The prevalence of HIV-1 integrase mutations related to resistance to the next-generation integrase inhibitor (INI), dolutegravir (DTG), was assessed in 440 INI-naïve subjects and in 120 patients failing a raltegravir (RTG)-containing regimen. Of the mutations selected by DTG in vitro, S153FY was not detected in any isolate while L101I and T124A were highly prevalent in both groups and significantly associated with non-B subtype. RTG-selected double and triple mutants, mostly the G140S/Q148H variant, were detected in only 32 (26.7%) RTG-treated patients. As L101I and T124A do not appear to exert any major effect in vivo and double and triple mutants resistant to DTG are infrequently selected by RTG, DTG can be effectively used in INI-naïve patients and may retain activity in many patients failing RTG.

Original language	English
Pages (from-to)	E428-E428-30
Journal	Clinical Microbiology and Infection
Volume	18
DOIs	https://doi.org/10.1111/j.1469-0691.2012.03917.x
Publication status	Published - 2012

Keywords

drug resistance
mutation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1469-0691.2012.03917.x

Cite this

Saladini, F., Meini, G., Bianco, C., Monno, L., Punzi, G., Pecorari, M., Borghi, V., Di Pietro, M., Filice, G., Gismondo, Micheli, V., Penco, G., Carli, T., De Luca, A., & Zazzi, M. (2012). Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients. Clinical Microbiology and Infection, 18, E428-E428-30. https://doi.org/10.1111/j.1469-0691.2012.03917.x

@article{0e8a7dc759034870a72586b9ca21ef0a,

title = "Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir na{\"i}ve and pretreated patients",

abstract = "The prevalence of HIV-1 integrase mutations related to resistance to the next-generation integrase inhibitor (INI), dolutegravir (DTG), was assessed in 440 INI-na{\"i}ve subjects and in 120 patients failing a raltegravir (RTG)-containing regimen. Of the mutations selected by DTG in vitro, S153FY was not detected in any isolate while L101I and T124A were highly prevalent in both groups and significantly associated with non-B subtype. RTG-selected double and triple mutants, mostly the G140S/Q148H variant, were detected in only 32 (26.7%) RTG-treated patients. As L101I and T124A do not appear to exert any major effect in vivo and double and triple mutants resistant to DTG are infrequently selected by RTG, DTG can be effectively used in INI-na{\"i}ve patients and may retain activity in many patients failing RTG.",

keywords = "drug resistance, mutation, drug resistance, mutation",

author = "F Saladini and G Meini and C Bianco and L Monno and G Punzi and M Pecorari and V Borghi and {Di Pietro}, M and G Filice and Gismondo and V Micheli and G Penco and T Carli and {De Luca}, Andrea and M. Zazzi",

year = "2012",

doi = "10.1111/j.1469-0691.2012.03917.x",

language = "English",

volume = "18",

pages = "E428--E428--30",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

publisher = "Oxford: Blackwell Science.",

}

Saladini, F, Meini, G, Bianco, C, Monno, L, Punzi, G, Pecorari, M, Borghi, V, Di Pietro, M, Filice, G, Gismondo, Micheli, V, Penco, G, Carli, T, De Luca, A & Zazzi, M 2012, 'Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients', Clinical Microbiology and Infection, vol. 18, pp. E428-E428-30. https://doi.org/10.1111/j.1469-0691.2012.03917.x

TY - JOUR

T1 - Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients

AU - Saladini, F

AU - Meini, G

AU - Bianco, C

AU - Monno, L

AU - Punzi, G

AU - Pecorari, M

AU - Borghi, V

AU - Di Pietro, M

AU - Filice, G

AU - Gismondo,

AU - Micheli, V

AU - Penco, G

AU - Carli, T

AU - De Luca, Andrea

AU - Zazzi, M.

PY - 2012

Y1 - 2012

N2 - The prevalence of HIV-1 integrase mutations related to resistance to the next-generation integrase inhibitor (INI), dolutegravir (DTG), was assessed in 440 INI-naïve subjects and in 120 patients failing a raltegravir (RTG)-containing regimen. Of the mutations selected by DTG in vitro, S153FY was not detected in any isolate while L101I and T124A were highly prevalent in both groups and significantly associated with non-B subtype. RTG-selected double and triple mutants, mostly the G140S/Q148H variant, were detected in only 32 (26.7%) RTG-treated patients. As L101I and T124A do not appear to exert any major effect in vivo and double and triple mutants resistant to DTG are infrequently selected by RTG, DTG can be effectively used in INI-naïve patients and may retain activity in many patients failing RTG.

AB - The prevalence of HIV-1 integrase mutations related to resistance to the next-generation integrase inhibitor (INI), dolutegravir (DTG), was assessed in 440 INI-naïve subjects and in 120 patients failing a raltegravir (RTG)-containing regimen. Of the mutations selected by DTG in vitro, S153FY was not detected in any isolate while L101I and T124A were highly prevalent in both groups and significantly associated with non-B subtype. RTG-selected double and triple mutants, mostly the G140S/Q148H variant, were detected in only 32 (26.7%) RTG-treated patients. As L101I and T124A do not appear to exert any major effect in vivo and double and triple mutants resistant to DTG are infrequently selected by RTG, DTG can be effectively used in INI-naïve patients and may retain activity in many patients failing RTG.

KW - drug resistance

KW - mutation

KW - drug resistance

KW - mutation

UR - http://hdl.handle.net/10807/40467

U2 - 10.1111/j.1469-0691.2012.03917.x

DO - 10.1111/j.1469-0691.2012.03917.x

M3 - Article

SN - 1198-743X

VL - 18

SP - E428-E428-30

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

ER -

Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this